Table 3.
All the QM statistics for whether the moderators have a significant effect on clinical remission rate
| (A) Clinical remission week 8 | |||
| Moderator | QM | df | p |
| Number of center | 0.0038 | 1 | 0.9506 |
| Prior anti-TNFα | 0.0884 | 1 | 0.7662 |
| Severity | 0.2327 | 1 | 0.6295 |
| Concomittant IM | 2.8879 | 1 | 0.0892 |
| Concomittant steroid | 3.1418 | 1 | 0.0763 |
| Publish style | 2.8879 | 1 | 0.0892 |
| (B) Clinical remission week 16 | |||
| Moderator | QM | df | p |
| Study design | 0.0183 | 1 | 0.8923 |
| Number of center | 0.0963 | 1 | 0.7563 |
| Prior anti-TNFα | 4.1836 | 1 | 0.0408 |
| Prior more than two anti-TNFα | 0.0006 | 1 | 0.9804 |
| Prior VDZ | 4.0142 | 1 | 0.0451 |
| Prior TOF | 0.1771 | 1 | 0.6739 |
| Severity | 0.9828 | 2 | 0.6118 |
| Concomittant IM | 1.6126 | 1 | 0.2041 |
| Concomittant steroid | 0.3863 | 1 | 0.5343 |
| Publish style | 0.0194 | 1 | 0.8892 |
| (C) Clinical remission month 6 | |||
| Moderator | QM | df | p |
| Study design | 0.3507 | 1 | 0.5537 |
| Number of center | 3.0936 | 1 | 0.0786 |
| Prior anti-TNFα | 8.2875 | 1 | 0.004 |
| Prior VDZ | 6.4679 | 1 | 0.011 |
| Severity | 1.386 | 1 | 0.2391 |
| Concomittant IM | 0.0321 | 1 | 0.8578 |
| Concomittant steroid | 1.3962 | 1 | 0.2374 |
| Publish style | 4.6219 | 1 | 0.0316 |
| (D) Clinical remission month 12 | |||
| Moderator | QM | df | p |
| Number of center | 1.0845 | 2 | 0.5814 |
| Prior anti-TNFα | 3.7936 | 1 | 0.0514 |
| Prior more than two anti-TNFα | 0.3586 | 1 | 0.5493 |
| Prior VDZ | 3.7217 | 1 | 0.0537 |
| Severity | 1.1402 | 1 | 0.2856 |
| Concomittant IM | 1.0255 | 1 | 0.3112 |
| Concomittant steroid | 0.637 | 1 | 0.4248 |
| Publish style | 0.005 | 1 | 0.9434 |
QM: test statistic for the omnibus test of moderators
TNF: tumor necrosis factor
df: degrees of freedom
VDZ: vedolizumab
TOF: tofacitinib
IM: immunomodulator